Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Protagonist Therapeutics (PTGX) Research & Development (2017 - 2025)

Protagonist Therapeutics' Research & Development history spans 9 years, with the latest figure at $46.4 million for Q4 2025.

  • For Q4 2025, Research & Development rose 32.82% year-over-year to $46.4 million; the TTM value through Dec 2025 reached $159.3 million, up 15.32%, while the annual FY2025 figure was $159.3 million, 15.32% up from the prior year.
  • Research & Development for Q4 2025 was $46.4 million at Protagonist Therapeutics, up from $40.0 million in the prior quarter.
  • Across five years, Research & Development topped out at $46.4 million in Q4 2025 and bottomed at $24.2 million in Q1 2021.
  • The 5-year median for Research & Development is $34.2 million (2022), against an average of $33.5 million.
  • The largest annual shift saw Research & Development surged 131.05% in 2021 before it crashed 31.26% in 2022.
  • A 5-year view of Research & Development shows it stood at $38.4 million in 2021, then fell by 22.12% to $29.9 million in 2022, then decreased by 3.3% to $28.9 million in 2023, then grew by 20.78% to $34.9 million in 2024, then surged by 32.82% to $46.4 million in 2025.
  • Per Business Quant, the three most recent readings for PTGX's Research & Development are $46.4 million (Q4 2025), $40.0 million (Q3 2025), and $37.0 million (Q2 2025).